X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SUN PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SUN PHARMA NOVARTIS/
SUN PHARMA
 
P/E (TTM) x 365.1 25.1 1,456.3% View Chart
P/BV x 18.0 3.7 490.8% View Chart
Dividend Yield % 1.6 0.6 255.8%  

Financials

 NOVARTIS   SUN PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-16
SUN PHARMA
Mar-17
NOVARTIS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs982842 116.6%   
Low Rs556572 97.2%   
Sales per share (Unadj.) Rs252.9131.6 192.2%  
Earnings per share (Unadj.) Rs62.132.7 190.0%  
Cash flow per share (Unadj.) Rs63.338.0 166.7%  
Dividends per share (Unadj.) Rs10.003.50 285.7%  
Dividend yield (eoy) %1.30.5 262.7%  
Book value per share (Unadj.) Rs363.6152.7 238.1%  
Shares outstanding (eoy) m31.962,399.26 1.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.05.4 56.6%   
Avg P/E ratio x12.421.6 57.2%  
P/CF ratio (eoy) x12.218.6 65.2%  
Price / Book Value ratio x2.14.6 45.7%  
Dividend payout %16.110.7 150.4%   
Avg Mkt Cap Rs m24,5801,696,877 1.4%   
No. of employees `0000.817.5 4.3%   
Total wages/salary Rs m1,80149,023 3.7%   
Avg. sales/employee Rs Th10,748.918,028.3 59.6%   
Avg. wages/employee Rs Th2,395.22,798.8 85.6%   
Avg. net profit/employee Rs Th2,641.14,479.5 59.0%   
INCOME DATA
Net Sales Rs m8,083315,784 2.6%  
Other income Rs m8296,232 13.3%   
Total revenues Rs m8,913322,016 2.8%   
Gross profit Rs m234100,893 0.2%  
Depreciation Rs m3712,648 0.3%   
Interest Rs m23,998 0.0%   
Profit before tax Rs m1,02590,479 1.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m1799 16.8%   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m75212,116 6.2%   
Profit after tax Rs m1,98678,462 2.5%  
Gross profit margin %2.931.9 9.1%  
Effective tax rate %73.413.4 547.8%   
Net profit margin %24.624.8 98.9%  
BALANCE SHEET DATA
Current assets Rs m12,678329,537 3.8%   
Current liabilities Rs m2,433178,870 1.4%   
Net working cap to sales %126.747.7 265.6%  
Current ratio x5.21.8 282.8%  
Inventory Days Days3379 41.4%  
Debtors Days Days2283 27.0%  
Net fixed assets Rs m69204,766 0.0%   
Share capital Rs m1602,399 6.7%   
"Free" reserves Rs m11,460363,997 3.1%   
Net worth Rs m11,621366,397 3.2%   
Long term debt Rs m014,361 0.0%   
Total assets Rs m14,400614,102 2.3%  
Interest coverage x570.523.6 2,414.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.5 109.2%   
Return on assets %13.813.4 102.8%  
Return on equity %17.121.4 79.8%  
Return on capital %23.624.8 94.9%  
Exports to sales %0.70-   
Imports to sales %18.60-   
Exports (fob) Rs m60NA-   
Imports (cif) Rs m1,503NA-   
Fx inflow Rs m18644,118 0.4%   
Fx outflow Rs m1,82124,484 7.4%   
Net fx Rs m-1,63519,634 -8.3%   
CASH FLOW
From Operations Rs m2,53170,822 3.6%  
From Investments Rs m-8,270-42,216 19.6%  
From Financial Activity Rs m-386-22,854 1.7%  
Net Cashflow Rs m-6,1256,107 -100.3%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 5.1 39.0%  
FIIs % 1.6 23.0 7.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 8.3 259.0%  
Shareholders   41,647 133,026 31.3%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   PFIZER  ABBOTT INDIA  PLETHICO PHARMA  WYETH LTD  TORRENT PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Losses; Capital Goods Sector Down 1.7%(11:30 am)

Indian share markets are presently trading on a negative note. Sectoral indices are trading in the red with stocks in the capital goods sector and metal sector witnessing maximum selling pressure.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 19, 2018 01:47 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS